1. Home
  2. Live Updates
  3. Prnewswire dizal

Live Breaking News & Updates on Prnewswire dizal

Stay informed with the latest breaking news from Prnewswire dizal on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Prnewswire dizal and stay connected to the pulse of your community

FDA Grants Breakthrough Therapy Designation To Sunvozertinib For The First-Line Treatment Of Patients With Advanced ...

(MENAFN - PR Newswire) SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) ... ...

Shanghai , China , Prnewswire-dizal , Drug-administration , Breakthrough-therapy-designation ,

FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , China , Shanghai , American , Xiaolin-zhang , Prnewswire-dizal , China-center , Twitter , Business-development , Linkedin , Drug-administration , American-society-of-clinical-oncology

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

/PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung...

Peking , Beijing , China , Shanghai , Chinese , Mengzhao-wang , Xiaolin-zhang , Prnewswire-dizal , Department-of-pulmonary-medicine , National-medical-products-administration , Business-development , Department-of-thoracic-oncology

Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH

/PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual...

China , United-states , California , San-diego , Shanghai , Chinese , American , Xiaolin-zhang , Prnewswire-dizal , China-national-medical-products-administration , Drug-administration , Business-development

Dizal Impresses With Its Differentiated Hematological Oncology Portfolio At 2023 ASH

Dizal Impresses With Its Differentiated Hematological Oncology Portfolio At 2023 ASH
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

China , United-states , California , Shanghai , San-diego , Chinese , American , Prnewswire-dizal , Xiaolin-zhang , Twitter , Drug-administration , Business-development

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B)...

San-diego , California , United-states , Shanghai , China , Peking , Beijing , Yuqing , Hubei , American , Jun-zhu , Prnewswire-dizal

Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients

Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

China , Shanghai , Chinese , Prnewswire-dizal , Xiaolin-zhang , Linkedin , Business-development , European-society-for-medical-oncology , Twitter , Demonstrates-best-in-class-potential , First-line-treatment , Mutation-positive-non-small-cell-lung-cancer

Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL

/PRNewswire/ -- Dizal announced today that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib,...

Shanghai , China , Chinese , Prnewswire-dizal , Xiaolin-zhang , Business-development , Linkedin , Drug-administration , Astrazeneca , Twitter , China-national-medical-products-administration , Fast-track-designation

Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology

/PRNewswire/ -- Dizal today announced the publication of the Phase I clinical data of golidocitinib for the treatment of relapsed or refractory (r/r)...

Japan , Shanghai , China , United-states , American , Japanese , Prnewswire-dizal , American-society-of-clinical-oncology , Business-development , American-society-of-hematology , Japanese-society-of-medical-oncology , European-society-for-medical-oncology

Dizal's Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations

/PRNewswire/ -- Dizal today announced that sunvozertinib has been approved by the National Medical Products Administration (NMPA) of China for the treatment of...

Shanghai , China , Peking , Beijing , United-states , American , Chinese , Xiaolin-zhang , Mengzhao-wang , Prnewswire-dizal , Twitter , Business-development